Ironwood Pharmaceuticals (United States)

Recent papers from Ironwood Pharmaceuticals (United States)

1. Actinic keratosis: A clinician’s guide to diagnosis and treatmentCleveland Clinic Journal of Medicine · 2026
2. Multifaceted burden of short bowel syndrome for patients and caregivers: The landmark surveyNutrition in Clinical Practice · 2026
3. Efficacy, safety, and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to standard of care (SOC) first-line (1L) therapy: The phase 2 TeLuRide-005 trial in stage 4 NSCLC.Journal of Clinical Oncology · 2026
4. In vitro concentration-dependent inhibition of early biofilm formation by Staphylococcus aureus isolated from dairy cattle using a bacteriophage cocktailBMC Veterinary Research · 2026
5. Patient and healthcare professional perspectives on short bowel syndrome management and preferred treatment attributesClinical Nutrition ESPEN · 2026
6. A post hoc analysis of linaclotide in pediatric patients with functional constipation and neurodevelopmental disordersJournal of Pediatric Gastroenterology and Nutrition · 2026
7. Disparities in Healthcare Seeking and Physician Diagnosis of Irritable Bowel Syndrome: Results from a US SurveyClinical Gastroenterology and Hepatology · 2026
8. Abstract PS1-11-07: First-in-human, phase 1a/b study of GDC-4198 (RGT-419B), a next generation CDK4/2 inhibitor, in patients with hormone receptor positive HER2- locally advanced/metastatic breast cancer (LA/mBC) who progressed on prior CDK4/6 inhibitorsClinical Cancer Research · 2026
9. Boltz-ABFE: Free Energy Perturbation without Crystal StructuresJournal of Chemical Theory and Computation · 2026
10. Sotorasib in Advanced KRAS G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesJTO Clinical and Research Reports · 2026
11. Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label TrialClinical Pharmacology in Drug Development · 2026
12. A Brief Report on Outcomes of Metastatic Non-Small Cell Lung Cancer: A Retrospective Observational Study in a Community Practice SettingCureus · 2025
13. Repression of the fliC gene as an immune evasion strategy in Yersinia ruckeri infection of rainbow trout (Oncorhynchus mykiss)Bulletin of the Veterinary Institute in Pulawy · 2025
14. Catalytic region mimetics in Na+ /H+ exchanger regulatory factor 4 suppress Guanylate Cyclase 2C activity to regulate enterotoxin triggered diarrheaJournal of Biological Chemistry · 2025
15. Cultural Ecosystem Services of Grassland Communities: A Case Study of Lubelskie ProvinceSustainability · 2025
16. Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare PopulationAdvances in Therapy · 2025
17. Drug-Induced Liver Injury Secondary to Endocrine Therapy With Aromatase Inhibitors: A Case ReportCureus · 2025
18. Oncoplastic Surgery: Where Are We Now?Journal of Surgical Oncology · 2024
19. Efficacy and safety of apraglutide in short bowel syndrome with intestinal failure and colon–in–continuity: A multicenter, open-label, metabolic balance studyClinical Nutrition · 2024
20. A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United StatesJournal of Managed Care & Specialty Pharmacy · 2024